search
Back to results

Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS)

Primary Purpose

Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome

Status
Active
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Understanding MRI in MS (website)
Control website
Sponsored by
Universitätsklinikum Hamburg-Eppendorf
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Multiple Sclerosis focused on measuring Patient education, Disease-specific knowledge, Shared decision making

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years 65 years
  • MRI within 6 weeks to 6 months
  • internet access AND
  • diagnosis of relapsing-remitting MS (RRMS) according to the McDonald criteria (Thompson et al., 2018), <10 years disease duration + active disease course (i.e. therapy change or new T2 lesion within the previous year) OR
  • clinically isolated syndrome (CIS) (with at least one MS-typical T2 lesion)

Exclusion Criteria:

  • diagnosis of secondary-progressive MS
  • diagnosis of primary-progressive MS
  • diagnosis or suspected central nervous system disease other than MS
  • severe cognitive deficit
  • major psychiatric illness
  • patients who are related to medical personnel

Sites / Locations

  • University Medical Centre Hamburg-Eppendorf

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Understanding MRI in MS (website)

Control website

Arm Description

Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.

Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).

Outcomes

Primary Outcome Measures

Magnetic resonance imaging risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0)
15-item magnetic resonance imaging-specific knowledge questionnaire (min. points 0, maximum points 22; higher values indicate greater knowledge)

Secondary Outcome Measures

Emotions and attitude towards magnetic resonance imaging (MRI-EMA)
Validated 10-item questionnaire on emotions and attitude towards magnetic resonance imaging, sub-scales (min. value: 1, max. value: 4; higher values indicate greater expression of the feature): 1) Fear of MRI scan, 2) Fear of MRI results, 3) Feeling of control, 4) Feeling of competence
Control preference scale (CPS)
Scale to assess autonomy preferences during medical decisions (5 categories between complete autonomy and paternalistic decision making as the extremes)
Threat by MS
Visual analogue scale to assess anxiety associated with disease progression (min. 0, max. 100; higher values indicate higher subjective threat)
Hospital Anxiety and Depression Scale (HADS)
Questionnaire to assess anxiety and depression (min. 0, max. 42 points (21 points for each subscale, subscales are added); higher values indicate more severe depression/anxiety)
Multifocal Approach to Sharing in Shared Decision Making (MAPPIN'SDM)
Tool to assess the amount of shared decision making during a patient-physician encounter (min. value 0, max. value 45; higher values indicated higher level of shared decision making)

Full Information

First Posted
January 25, 2019
Last Updated
December 5, 2022
Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Sanofi
search

1. Study Identification

Unique Protocol Identification Number
NCT03872583
Brief Title
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
Acronym
UMIMS
Official Title
Understanding Magnetic Resonance Imaging in Multiple Sclerosis - a Randomized, Controlled, Double Blind Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Active, not recruiting
Study Start Date
March 15, 2019 (Actual)
Primary Completion Date
December 1, 2022 (Actual)
Study Completion Date
July 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
Sanofi

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Magnetic resonance imaging (MRI) results play a major role in the lives of people with multiple sclerosis (pwMS). Even though MRI is used for diagnosis, prognosis and therapy control, pwMS' knowledge concerning this complex matter is scarce. Without adequate disease-specific knowledge, pwMS cannot truly make an informed choice when considering their MRI results (e.g. necessity of future MRI scans or therapy change). The investigators have developed an innovative, evidence-based and interactive online education tool called "Understanding MRI in MS", which incorporates all relevant information about MRI in MS and its implications in disease management. In this randomized, controlled and double-blind trial the tool's effect on MRI-specific knowledge, self-perceived competence and involvement in medical decision, that are based on MRI results will be assessed.
Detailed Description
For the randomized controlled trial (RCT), n=120 consecutive patients of 4 centers, for whom a brain (or brain and spine) MRI scan is planned within the next 6 months, will be invited to participate in the trial. Eligible patients will be asked to participate, and, if willing, will receive information about the study by the recruiting physician and written consent will be obtained. Participants will then answer a baseline questionnaire including demographic data, numeracy, attitude and emotions towards MRI (MRI-emotions and attitude questionnaire, MRI-EMA, newly developed) and MRI-specific knowledge (MRI-risk knowledge questionnaire 2.0, MRI-RIKNO 2.0, newly developed). Patients will then be randomized into two groups: The intervention group of n=60 participants gets access to the web-based educational tool, the control group of n=60 to a sham intervention with standard information on MRI. Participants will be asked to provide an e-mail address via which the login for the educational tool will be delivered. After two weeks participants will be asked to fill out the following tools: Primary endpoint MRI-risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0) (newly developed) MRI-emotions and attitude questionnaire (MRI-EMA) (newly developed) Threat by MS Autonomy preferences (Control Preference Scale) Subjective knowledge (VAS scale) (22) Within the course of 2 weeks to 6 months the scheduled MRI will take place, followed by a patient-physician encounter, in which the MRI results are discussed. Directly after this encounter patients and physicians will be asked to answer MAPPIN'SDM questionnaires to assess perceived shared decision making behaviour and realization of autonomy preferences (Control reference scale). All patients will also be asked questions concerning any decisions taken based on the MRI, either a start/change of treatment or agreement on a new MRI in a defined time-frame. N=5 patients of each arm in the study center in Hamburg will be randomly selected and the communication of results during this consultation will be audiotaped and evaluated using the MAPPIN'SDM observer rating approach. In a telephone follow-up after 6 months, implementation of the decisions will be checked.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Keywords
Patient education, Disease-specific knowledge, Shared decision making

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, controlled, double-blind trial
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Participants, physicians, outcome assessors and investigator will be blinded.
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Understanding MRI in MS (website)
Arm Type
Experimental
Arm Description
Participants will receive access to a newly developed, innovative, interactive and evidence-based education tool about magnetic resonance imaging in multiple sclerosis.
Arm Title
Control website
Arm Type
Active Comparator
Arm Description
Participants will receive access to a specifically designed control website containing the information about magnetic resonance imaging in multiple sclerosis, that is freely available on the websites of major European multiple sclerosis self help organization (Australia, Belgium, Canada, France, Germany, Great Britain, Netherland, USA).
Intervention Type
Other
Intervention Name(s)
Understanding MRI in MS (website)
Intervention Description
Access to an innovative, interactive and evidence-based online education tool about MRI in multiple sclerosis.
Intervention Type
Other
Intervention Name(s)
Control website
Intervention Description
Access to a specifically designed control website containing information on MRI in MS freely available on the websites of major European MS self-help organizations.
Primary Outcome Measure Information:
Title
Magnetic resonance imaging risk knowledge questionnaire 2.0 (MRI-RIKNO 2.0)
Description
15-item magnetic resonance imaging-specific knowledge questionnaire (min. points 0, maximum points 22; higher values indicate greater knowledge)
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Emotions and attitude towards magnetic resonance imaging (MRI-EMA)
Description
Validated 10-item questionnaire on emotions and attitude towards magnetic resonance imaging, sub-scales (min. value: 1, max. value: 4; higher values indicate greater expression of the feature): 1) Fear of MRI scan, 2) Fear of MRI results, 3) Feeling of control, 4) Feeling of competence
Time Frame
Baseline, 2 weeks
Title
Control preference scale (CPS)
Description
Scale to assess autonomy preferences during medical decisions (5 categories between complete autonomy and paternalistic decision making as the extremes)
Time Frame
Baseline, 2 weeks, after patient-physician encounter (i.e. 4 weeks to 6 months after baseline)
Title
Threat by MS
Description
Visual analogue scale to assess anxiety associated with disease progression (min. 0, max. 100; higher values indicate higher subjective threat)
Time Frame
baseline, 2 weeks
Title
Hospital Anxiety and Depression Scale (HADS)
Description
Questionnaire to assess anxiety and depression (min. 0, max. 42 points (21 points for each subscale, subscales are added); higher values indicate more severe depression/anxiety)
Time Frame
Baseline, 2 weeks
Title
Multifocal Approach to Sharing in Shared Decision Making (MAPPIN'SDM)
Description
Tool to assess the amount of shared decision making during a patient-physician encounter (min. value 0, max. value 45; higher values indicated higher level of shared decision making)
Time Frame
after patient-physician-encounter (i.e. 4 weeks to 6 months after baseline)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years 65 years MRI within 6 weeks to 6 months internet access AND diagnosis of relapsing-remitting MS (RRMS) according to the McDonald criteria (Thompson et al., 2018), <10 years disease duration + active disease course (i.e. therapy change or new T2 lesion within the previous year) OR clinically isolated syndrome (CIS) (with at least one MS-typical T2 lesion) Exclusion Criteria: diagnosis of secondary-progressive MS diagnosis of primary-progressive MS diagnosis or suspected central nervous system disease other than MS severe cognitive deficit major psychiatric illness patients who are related to medical personnel
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christoph Heesen, Prof.
Organizational Affiliation
University Medical Center Hamburg-Eppendorf; Institute for Neuroimmunology and Multiple Sclerosis
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Medical Centre Hamburg-Eppendorf
City
Hamburg
ZIP/Postal Code
20246
Country
Germany

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
25415501
Citation
Brand J, Kopke S, Kasper J, Rahn A, Backhus I, Poettgen J, Stellmann JP, Siemonsen S, Heesen C. Magnetic resonance imaging in multiple sclerosis--patients' experiences, information interests and responses to an education programme. PLoS One. 2014 Nov 21;9(11):e113252. doi: 10.1371/journal.pone.0113252. eCollection 2014.
Results Reference
background
PubMed Identifier
28764895
Citation
Gaissmaier W, Giese H, Galesic M, Garcia-Retamero R, Kasper J, Kleiter I, Meuth SG, Kopke S, Heesen C. Numeracy of multiple sclerosis patients: A comparison of patients from the PERCEPT study to a German probabilistic sample. Patient Educ Couns. 2018 Jan;101(1):74-78. doi: 10.1016/j.pec.2017.07.018. Epub 2017 Jul 17.
Results Reference
background
PubMed Identifier
26430887
Citation
Heesen C, Kasper J, Fischer K, Kopke S, Rahn A, Backhus I, Poettgen J, Vahter L, Drulovic J, Van Nunen A, Beckmann Y, Liethmann K, Giordano A, Fulcher G, Solari A; AutoMS-group. Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0)--Development of an Outcome Instrument for Educational Interventions. PLoS One. 2015 Oct 2;10(10):e0138364. doi: 10.1371/journal.pone.0138364. eCollection 2015.
Results Reference
background
PubMed Identifier
17400253
Citation
Heesen C, Kasper J, Kopke S, Richter T, Segal J, Muhlhauser I. Informed shared decision making in multiple sclerosis--inevitable or impossible? J Neurol Sci. 2007 Aug 15;259(1-2):109-17. doi: 10.1016/j.jns.2006.05.074. Epub 2007 Apr 2.
Results Reference
background
PubMed Identifier
18824488
Citation
Craig P, Dieppe P, Macintyre S, Michie S, Nazareth I, Petticrew M; Medical Research Council Guidance. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008 Sep 29;337:a1655. doi: 10.1136/bmj.a1655.
Results Reference
background
PubMed Identifier
15177841
Citation
Boeije HR, Janssens AC. 'It might happen or it might not': how patients with multiple sclerosis explain their perception of prognostic risk. Soc Sci Med. 2004 Aug;59(4):861-8. doi: 10.1016/j.socscimed.2003.11.040.
Results Reference
background
PubMed Identifier
9505581
Citation
Degner LF, Sloan JA, Venkatesh P. The Control Preferences Scale. Can J Nurs Res. 1997 Fall;29(3):21-43.
Results Reference
background
PubMed Identifier
27536077
Citation
Riechel C, Alegiani AC, Kopke S, Kasper J, Rosenkranz M, Thomalla G, Heesen C. Subjective and objective knowledge and decisional role preferences in cerebrovascular patients compared to controls. Patient Prefer Adherence. 2016 Aug 2;10:1453-60. doi: 10.2147/PPA.S98342. eCollection 2016.
Results Reference
background
PubMed Identifier
22514677
Citation
Kasper J, Hoffmann F, Heesen C, Kopke S, Geiger F. MAPPIN'SDM--the multifocal approach to sharing in shared decision making. PLoS One. 2012;7(4):e34849. doi: 10.1371/journal.pone.0034849. Epub 2012 Apr 13. Erratum In: PLoS One. 2012;7(6). doi:10.1371/annotation/3e489f03-e7e7-4b41-827e-caa85bb06466.
Results Reference
background
PubMed Identifier
6880820
Citation
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x.
Results Reference
background
PubMed Identifier
33298133
Citation
Schiffmann I, Freund M, Vettorazzi E, Stellmann JP, Heyer-Borchelt S, D'Hooghe M, Haussler V, Rahn AC, Heesen C. Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS-understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. Trials. 2020 Dec 9;21(1):1008. doi: 10.1186/s13063-020-04855-5.
Results Reference
derived

Learn more about this trial

Understanding Magnetic Resonance Imaging in Multiple Sclerosis

We'll reach out to this number within 24 hrs